24 June 2025 – Biosceptre International Limited (“Biosceptre” or “the Company”) is pleased to announce a placement of up to £10 million to existing shareholders who are eligible to participate under the laws and securities regulations of their respective jurisdictions.
The placement reflects the Company’s ongoing commitment to maintaining the momentum achieved over the last few years and will fund the next stage of preclinical work and preparation for clinical trials, supported by its engaged and growing shareholder base.
Please note, this placement is not being offered to U.S. residents. Further, Biosceptre advises that this placement does not constitute an offer of securities in any jurisdiction in which such an offer would be unlawful or require registration.
Shareholders that are not residents of the US will receive further communication with full details of the placement process and participation instructions.
Biosceptre thanks its shareholders for their ongoing support and looks forward to continued progress in its mission to deliver innovative cancer therapies.
For further information, please contact:
Investor Relations
info@biosceptre.com